



Safiyya Dharssi

Safiyya is currently a Director, in the Global Policy Team at Pfizer, focused on advancing patient access to rare diseases and personalized medicine treatments. In this role, her responsibilities span regulatory, reimbursement and broader health policy related issues, working closely with the global stakeholder community to advance policy issues of mutual interest. Safiyya is actively involved in advancing rare disease national frameworks globally and also involved in patient focused drug development projects in the US. More recently, her work has evolved to look at policy solutions for innovative science areas such as gene therapy and immuno-oncology. Prior to this role, Safiyya was a part of the trade association, PhRMA's International Policy group, where she lead the research-based biopharmaceutical industry efforts around healthcare reform and access issues in the Asia Pacific and the Latin America region. Her work involved engagement with the WHO, OECD and national regulatory and advocacy organizations. Along with industry experience, Safiyya has also held roles in non-profit and academia. Her previous work included identifying solutions to the under-representation of older adults in clinical trials and was a project lead of the S.T.A.R (Senior's Together in Aging Research) project at the University of Iowa's Center on Aging.

Safiyya holds an MSPH in Health Policy from the Johns Hopkins School of Public Health and a Bachelor of Arts & Science focusing in Pharmacology and International Studies from McGill University. Safiyya is a member of the National Organization for Rare Disease (NORD) Corporate Council, the Personalized Medicine Coalition (PMC) and the Alliance for Regenerative Medicine (ARM). She also serves on the leadership team of Pfizer's Global Asian Alliance, advancing the career and professional development of colleagues with diverse backgrounds at Pfizer.